Home › New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA (sitagliptin) Compared to Placebo
 

Keywords :   


New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA (sitagliptin) Compared to Placebo

2014-06-14 19:01:06| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions. Language: English read more

Tags: to with type shows

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Teenagers could help fill train driver shortage
16.05Peak-time ScotRail fares scrapped for further three months
16.05Japanese brand to launch TVs 'Powered by TiVo'
16.05Disney and WBD announce Disney+, Hulu, Max bundle
16.05VIZIO reports Q1 2024 financial results
16.05Pixalate releases Q1 2024 CTV ad supply chain report
16.05'Time running out' plea over shipyard's future
16.05Eastern North Pacific Tropical Weather Outlook
More »